Waxman/Hatch Reforms Preserve Declaratory Judgment “Reasonable Apprehension” Test – Court
This article was originally published in The Pink Sheet Daily
Executive Summary
Newark, N.J. federal judge rejects Dr. Reddy’s argument that the Medicare Rx law’s generic drug reform provisions were intended to create a “case or controversy” when an ANDA filer is not sued for infringement within 45 days.
You may also be interested in...
Zofran Patent Ruling
Two method-of-use patents for GlaxoSmithKline's Zofran are valid and infringed by Teva's ANDA, Wilmington, Del. federal Judge Gregory Sleet ruled Aug. 20
Zofran Patent Ruling
Two method-of-use patents for GlaxoSmithKline's Zofran are valid and infringed by Teva's ANDA, Wilmington, Del. federal Judge Gregory Sleet ruled Aug. 20
Par Acquisition Of Kali Will Help Boost Product Offerings 50% In Two Years
Par will pay $135 mil. for the New Jersey-based generic drug firm. The combined company will have 37 pending ANDAs, including first-to-file application for generic version of J&J's Ultracet.